Rebecca Ritchie

Endothelium-dependent relaxation is impaired in Schlager hypertensive (BPH/2J) mice by region-specific mechanisms in conductance and resistance arteries.

Maria Jelinic, Kristy L Jackson, Kelly O'Sullivan, Jaideep Singh, Thomas Giddy, Minh Deo, Laura J Parry, Rebecca H Ritchie, Owen L Woodman, Geoffrey A Head, Chen Huei Leo, Cheng Xue Qin

Journal article  |  2023  |  Life Sci

AIMS: Endothelial dysfunction and arterial stiffness are hallmarks of hypertension, and major risk factors for cardiovascular dise..

A high-sucrose diet exacerbates the left ventricular phenotype in a high fat-fed streptozotocin rat model of diabetic cardiomyopathy.

Anida Velagic, Mandy Li, Minh Deo, Jasmin Chendi Li, Helen Kiriazis, Daniel G Donner, Dovile Anderson, Miles J De Blasio, Owen L Woodman, Barbara K Kemp-Harper, Cheng Xue Qin, Rebecca H Ritchie

Journal article  |  2023  |  Am J Physiol Heart Circ Physiol

Left ventricular (LV) dysfunction is an early, clinically detectable sign of cardiomyopathy in type 2 diabetes mellitus (T2DM) tha..

PS-BPB02-3: TARGETING FORMYL PEPTIDE RECEPTORS AS A NOVEL APPROACH TO TREAT HYPERTENSION-INDUCED ADVERSE CARDIOVASCULAR REMODELLING AND DYSFUNCTION

Jaideep Singh, Kristy L Jackson, Audrey Gumanti, Haoyun Fang, Owen L Woodman, Rebecca H Ritchie, David Greening, Geoffrey A Head, Chengxue Qin

Journal article  |  2023  |  Journal of Hypertension

Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study

A Sharma, S Wood, JS Bell, MJ De Blasio, J Ilomäki, RH Ritchie

Journal article  |  2023  |  The Lancet Regional Health - Western Pacific

Background: Sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce ma..

Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery.

Lauren T May, Belinda A Bartolo, David G Harrison, Tomasz Guzik, Grant R Drummond, Gemma A Figtree, Rebecca H Ritchie, Kerry-Anne Rye, Judy B de Haan

Journal article  |  2022  |  Clin Sci (Lond)

Cardiovascular disease (CVD) remains the leading cause of death worldwide. An ongoing challenge remains the development of novel p..

Investigating potential sex-specific differences of newer glucose-lowering therapies on cardiovascular outcomes in Victorian patients with diabetes

Abhipree Sharma, Stephen Wood, Miles De Blasio, Simon Bell, Jenni Ilomäki, Rebecca Ritchie

Journal article  |  2022  |  Journal of Molecular and Cellular Cardiology

Current landscape of preclinical models of diabetic cardiomyopathy.

Darnel Prakoso, Miles J De Blasio, Mitchel Tate, Rebecca H Ritchie

Journal article  |  2022  |  Trends Pharmacol Sci

Patients with diabetes have an increased risk of developing heart failure, preceded by (often asymptomatic) cardiac abnormalities,..

Advancing cardiovascular translational research.

Rebecca H Ritchie, Suowen Xu, Serena Zacchigna

Journal article  |  2022  |  Trends Pharmacol Sci

In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function

Bianca C Bernardo, Gunes S Yildiz, Helen Kiriazis, Claudia A Harmawan, Celeste MK Tai, Rebecca H Ritchie, Julie R McMullen

Journal article  |  2022  |  CELLS

MicroRNA 34a (miR-34a) is elevated in the heart in a setting of cardiac stress or pathology, and we previously reported that inhib..

Novel strategies to promote resolution of inflammation to treat lower extremity artery disease.

Qian Zhang, Fengyang Li, Rebecca H Ritchie, Owen L Woodman, Xiaojun Zhou, Cheng Xue Qin

Journal article  |  2022  |  Curr Opin Pharmacol

Lower extremity artery disease (LEAD) is a chronic inflammatory disease that occurs when atherosclerotic plaques form in the lower..